Biocon Biologics
Vann Bennett is a seasoned professional in the pharmaceutical and healthcare industry with extensive experience in account management and strategic leadership. Currently serving as the National Account Director at Biocon Biologics since January 2024, Vann previously held the position of National Account Manager at IQVIA from June 2020 to January 2024. Earlier career roles include Field Market Access Director at Syneos Health Commercial Solutions, National Account Executive at Nalpropion Pharmaceuticals, and Senior Strategic Account Executive at Boehringer Ingelheim, where Vann worked from February 1999 to August 2016. Vann holds a Bachelor of Applied Science degree in Communication Sciences and Disorders from Texas Women's University, complemented by foundational education at Austin Peay State University.
This person is not in any teams
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics